Biomarkers Market Size & Share 2025 – 2034

Biomarkers Market Size

The global biomarkers market was valued at USD 85.9 billion in 2025 and is projected to expand from USD 95.3 billion in 2026 to USD 244.8 billion by 2034, registering a CAGR of 12.3% during the 2026–2034 period.

Biomarkers are biological molecules and include proteins, genes, and other molecules. These molecules are found in the blood, tissues, or body fluids that help in identifying biological processes or disease conditions. These biomarkers are utilized in early detection, diagnosis, monitoring treatment response, and designing personalized therapies to improve patient outcomes.
 

Market Overview & Key Takeaways

North America dominated the biomarkers market, generating USD 37.7 billion in 2025, with the U.S. contributing USD 31.6 billion in revenue.
 

Asia Pacific, led by Japan, is expected to witness lucrative growth during 2026–2034.
 

Hospitals emerged as the leading end-use segment, accounting for 38.5% market share in 2025.
 

The cancer segment held the largest share by disease type, representing 38.5% of total revenue in 2025.
 

Diagnostics dominated the application segment, capturing a 40.6% share in 2025.
 

The consumables segment generated USD 41.72 billion in 2025 and is projected to grow at a CAGR of 12.3% during the forecast period.
 

Market Size & Forecast Snapshot

2025 Market Size: USD 85.9 Billion
 

2034 Projected Market Size: USD 244.8 Billion
 

CAGR (2026–2034): 12.3%
 

Largest Regional Market: North America
 

Fastest-Growing Region: Asia Pacific
 

The global biomarkers market is expanding rapidly, fueled by the rising prevalence of chronic diseases. According to the World Health Organization (WHO), noncommunicable diseases (NCDs) cause 41 million deaths annually, representing 74% of global mortality. Of these, 17 million are premature deaths, with 86% occurring in low- and middle-income countries. This growing burden underscores the need for advanced biomarkers to enable early detection, accurate diagnosis, personalized treatment, and effective monitoring of disease progression and therapy outcomes.
 

Innovations in personalized medicine are further accelerating market growth. Non-invasive methods such as liquid biopsies allow early diagnosis and real-time monitoring, with Guardant360 CDx demonstrating clinical validity in identifying KRAS p.G12C–mutant non-small cell lung cancer (NSCLC). Effectiveness improves when combined with tissue-based tests, ensuring comprehensive mutation detection. In addition, artificial intelligence and multi-omics approaches enhance diagnostic accuracy by integrating genomic, proteomic, and metabolomic data. Ongoing advancements in genomic and proteomic technologies, coupled with rising research and development investments, continue to strengthen the market outlook.
 

Biomarkers Market Trends

• Genomic and Proteomic Advancements

• Cutting-edge biomarker technologies market innovations are transforming research and clinical applications.
   
• Genomic tools accelerate identification of genetic biomarkers, while proteomic platforms provide insights into protein expression patterns, disease heterogeneity, and drug resistance.
   
• Together, these technologies support the development of precision therapies tailored to specific biomarker profiles.
   

• 2. Next-Generation Sequencing (NGS)

• NGS has become a cornerstone of biomarker research, enabling simultaneous analysis of multiple genes.
   
• It helps identify genetic mutations, fusions, and alterations associated with various diseases, guiding targeted therapy selection and predicting patient drug responses.
   
• Example: In August 2024, Illumina’s TruSight Oncology Comprehensive test received FDA approval. This 500+ gene panel rapidly matches patients to therapies by identifying relevant genetic mutations.
   

• 3. Liquid Biopsy Adoption

• The biomarker tests market is increasingly shaped by liquid biopsy technologies.
   
• These non-invasive tests detect circulating tumor DNA (ctDNA) and cell-free RNA (cfRNA) in blood samples.
   
• Benefits include monitoring disease progression, detecting minimal residual disease, and identifying molecular changes for informed therapeutic decisions.
   

Biomarkers Market Analysis

Based on product and services, the market is segmented into consumables, software, and services. The consumables segment held revenue of USD 41.72 billion in 2025 and the segment is poised for significant growth at a CAGR of 12.3% during the forecast period.
 

• Consumables, which include reagents, assay kits, and microplates, are manufactured under strict quality control measures, ensuring consistent performance across experiments. This reliability is necessary for generating reproducible results in biomarker studies, specifically in clinical diagnostics and drug discovery. For instance, Thermo Fisher Scientific’s ELISA kits provide high-sensitivity biomarker detection for disease research, confirming accurate and reproducible outcomes.
   
• Additionally, advanced consumables are designed to increase the sensitivity and specificity of biomarker assays. For example, Bio-Rad’s Droplet Digital PCR (ddPCR) reagents enable precise detection of low-abundance biomarkers in oncology and infectious disease diagnostics, minimizing false positives or negatives.
   

• Furthermore, consumables are optimized for use with advanced platforms such as mass spectrometry, next-generation sequencing (NGS), and liquid chromatography. This compatibility confirms seamless integration into workflows, which helps in improving the performance of these technologies in biomarker discovery and analysis, thereby driving market growth.
  
   

Learn more about the key segments shaping this market

Download Free PDF

Based on biomarker type, the biomarkers market is bifurcated into safety biomarkers, efficacy biomarkers, predictive biomarkers, surrogate biomarkers, pharmacodynamic biomarkers, prognostics biomarkers, and validation biomarkers.
 

The safety biomarkers segment held a 25.3% share of the global market in 2025 and is expected to witness strong growth, reaching USD 63.2 billion by 2034. Safety biomarkers enable the early detection of drug-induced toxicity across critical organs such as the kidneys, heart, and nervous system, often before clinical symptoms emerge.
 

For example, kidney injury molecule-1 (KIM-1) is widely used for the early identification of nephrotoxicity, helping prevent severe renal damage. By identifying safety risks early in drug development, these biomarkers reduce late-stage clinical failures, lower R&D costs, and support the development of safer therapeutics.
 

Based on application, the biomarkers market is bifurcated into diagnostics, drug discovery and development, personalized medicine, disease risk assessment, and other applications. The diagnostics segment accounted for a 40.6% market share in 2025.
 

• Biomarkers enable the identification of diseases at an early stage, often before clinical symptoms manifest. Early detection helps in improving prognosis and allows for timely interventions. For example, prostate-specific antigen (PSA) is a widely used biomarker for early detection of prostate cancer, significantly improving treatment outcomes.
   
• Many biomarkers can be detected through non-invasive or minimally invasive methods such as blood, urine, or saliva tests. This improves patient compliance and minimizes the risks and discomfort associated with traditional diagnostic methods such as biopsies.
   
• Furthermore, biomarkers allow for continuous or periodic monitoring of disease progression and treatment efficacy.
   
• Moreover, innovations in diagnostic technologies have improved biomarker detection sensitivity and accuracy, helping in expanding their clinical utility. For instance, next-generation sequencing (NGS) allows comprehensive genetic profiling for precision diagnostics in oncology, whereas mass spectrometry improves the detection of low-abundance biomarkers in metabolic and infectious diseases. Thus, propelling market growth.
   

Based on disease type, the biomarkers market is bifurcated into cancer, cardiovascular diseases, neurological diseases, immunological diseases, and other disease types. The cancer segment accounted for a 38.5% market share in 2025.
 

• The rising prevalence of cancer is one of the key catalysts for the growth of the segment.
   
• Biomarkers are important for identifying cancers at a very early stage, which helps in improving the chances of successful treatment. For example, the prostate-specific antigen (PSA) is used for early detection of prostate cancer, while CA-125 serves as an indicator for ovarian cancer.
   
• Additionally, biomarkers also provides molecular-level insights that help in distinguishing between benign and malignant tumors. For instance, cytokeratin fragments (CYFRA 21-1) are used to diagnose non-small cell lung cancer (NSCLC), which ensures accurate and timely intervention.
   
• Further, biomarkers help in post-treatment surveillance to identify cancer recurrence. For instance, elevated alpha-fetoprotein (AFP) levels in liver cancer patients may signal disease recurrence, prompting timely intervention, thereby escalating the market growth.
   

Based on end use, the biomarkers market is bifurcated into hospitals, diagnostic laboratories, academic and research institutions, and other end users. The hospitals segment accounted for a 38.5% market share in 2025.
 

• The growth of the segment can be attributed to the ability of the hospital to manage a large volume of patient pool, suffering from chronic diseases such as cancer, cardiovascular diseases, neurological disorders, among others, which includes both inpatient and outpatient. For instance, the Manipal Hospital of India, known as the second-largest hospital chain in the nation, annually observes a 400,000 cancer patient visit to their hospital.
   
• Hospitals use biomarkers to monitor the effectiveness of treatments in real-time, which allows doctors to adjust therapies quickly according to patients' needs for better outcomes and minimize side effects.
   

• Additionally, the growing demand for non-invasive biomarker test treatment such as liquid biopsy and companion diagnostics has stimulated the adoption of these technologies in the hospitals. Since these advanced technologies require highly skilled personnel which is readily available in the hospital setting, thereby the segment remains at the forefront in the rapidly evolving market of biomarkers.

The North America biomarkers market is accounted for USD 37.7 billion revenues in 2025, forecasted to reach USD 97.5 billion by 2034. The U.S. dominated the North America market with the largest revenue of USD 31.6 billion in 2025.
 

• The increasing prevalence of the chronic diseases such as cardiovascular diseases, neurological diseases, cancer in the U.S. are the key driver for the growth of the market in the U.S.
   
• For instance, as per the data from the American Cancer Society in 2025, around 2,041,910 new cases of cancer are expected to be diagnosed, and 618,120 cases of cancer related deaths is projected to occur in the U.S.
   
• Thus, this rising burden of the chronic diseases are propelling the market in the U.S. as many pharmaceutical and biotechnology companies, hospitals and research institutes are undertaking various research to develop advanced diagnostic solutions and therapies to the combat the disease in the country.
   
• Europe: The UK biomarkers market is expected to register significant growth from 2025 to 2034, supported by a regional CAGR of 12.1% and a market value of USD 18.78 billion in 2025, driven by the rising prevalence of chronic diseases such as cardiovascular disorders, cancer, neurological conditions, and immunological diseases, which is accelerating demand for biomarker-based diagnostics and precision medicine solutions.
   

• For instance, according to the British Heart Foundation, over 7.6 million people in the UK are living with heart and circulatory diseases, including over 4 million men and 3.6 million women. With an aging population and improved survival rates following cardiovascular events, these numbers are expected to rise significantly. Projections indicate that by 2030, the number of individuals affected could increase by 1 million, reaching 2 million more than current figures by 2040.
   
• Further, the growth of the market in this region is anticipated to be bolstered by the UK government's commitment towards tackling chronic conditions via initiatives covering public health campaigns such as “Clear on Cancer,” and formulation of effective guidelines.
   

Asia Pacific: Japan biomarkers market is anticipated to witness lucrative growth between 2025 – 2034.
 

• The country as one of speediest aging population which needs frequent health monitoring. For instance, according to the World Health Organization, in 2021, Japan's elderly population, aged 65 and above, comprised 29.1% of the total population.
   
• This demographic shift has led to a rise in age-related diseases, with chronic diseases such as cancer being the leading cause of death, accounting for 27% of all fatalities in Japan, as reported by the National Cancer Center Japan in 2022. Thus, this rising disease burden has surged the demand for effective targeted therapies, escalating the growth of the biomarkers in Japan.
   

Middle East and Africa: The in Saudi Arabia biomarkers market size is expected to experience significant and promising growth from 2026 to 2034.
 

• Saudi Arabia has experienced rise in early chronic disease detection due to growing awareness and improved screening programs. Thus, this trend encourages earlier treatment and heightens the demand for biomarkers.
   
• The rising need for diagnostics and care is further fueled by public health campaigns and national screening initiatives, resulting in significant market growth in the region.
   

Biomarkers Market Share

The top 4 players of the market accounted for approximately 45% of the market share which includes companies such as Abbott Laboratories, F. Hoffmann-La Roche, Illumina, Thermo Fisher Scientific, among others. With every firm introducing new products such as instruments, kits, assay and using advanced technologies, modernization is extremely important.
 

Moreover, strategic partnerships with research institutes, and government agencies play a primary role in advancing the development of new products and getting the necessary permits. The enhancement of public awareness about chronic diseases and its health impact through the social media platform, will encourage more individuals to seek the treatment, assisting market players to strengthen their position in this growing sector.
 

Biomarkers Market Companies

Some of the eminent market participants operating in the biomarkers industry include:

• Abbott Laboratories
• Agilent Technologies
• Bio-Rad Laboratories
• Becton, Dickinson and Company
• Eurofins Scientific
• Epigenomics
• F. Hoffmann-La Roche
• GE Healthcare
• Illumina
• Johnson & Johnson
• Merck KGaA
• PerkinElmer
• QIAGEN
• Siemens Healthineers
• Thermo Fisher Scientific
   
• F. Hoffmann-La Roche Ltd has strong global workforce of approximately 100,000+ employees, which enables the company to drive innovation, and deliver high-quality solutions.
   
• Agilent Technologies has robust geographical presence which enables it to enhance its market reach. Agilent Technologies operates in more than 110 countries thus comprising of a strong distribution network.
   
• Abbott Laboratories offer wide array of diagnostic solutions such as advanced biomarker assays (including its innovative range of cardiac biomarkers), to enable early and accurate disease detection.
   

Biomarkers Industry News:

• In August 2024, Illumina, Inc. received FDA approval for its in vitro diagnostic test, TruSight Oncology Comprehensive, which analyzes over 500 genes in a patient's solid tumor. This test aims to enhance the identification of oncology biomarkers, marking a major advancement in personalized cancer treatment by enabling more precise and targeted therapies.
   

The biomarkers market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2022 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product and Services

• Consumables
• Software
• Services

Market, By Biomarker Type

• Safety biomarkers
• Efficacy biomarkers
• Predictive biomarkers
• Surrogate biomarkers
• Pharmacodynamic biomarkers
• Prognostics biomarkers
• Validation biomarkers

Market, By Application

• Diagnostics
• Drug discovery and development
• Personalized medicine
• Disease risk assessment
• Other applications

Market, By Disease Type

• Cancer
• Cardiovascular diseases
• Neurological diseases
• Immunological diseases
• Other disease types

Market, By End Use

• Hospitals
• Diagnostic laboratories
• Academic and research institutions
• Other end use

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE